Search results
Results From The WOW.Com Content Network
Six months ago Cassava Sciences (SAVA) had a problem. A citizen petition was logged with the FDA calling for a halt on the company's simufilam drug for the treatment of Alzheimer's Disease. The ...
With the update, HC Wainwright has upgraded Cassava Sciences’ stock from Neutral to Buy, with a price target of $116, an upside of over 290%. In the letter, Rick highlighted completing the ...
The stock tumbled over 20% following a fireside chat, where CEO Remi Barbier outlined the progress being made in bringing simufilam, Cassava’s controversial Alzheimer’s drug candidate, to ...
Cassava Sciences (SAVA) hogged the headlines last year both for good and bad reasons. The company’s Alzheimer’s disease (AD) candidate simufilam showed exceptional results in clinical trials ...
Since making some big moves last month Cassava Sciences (NASDAQ:SAVA) stock has largely traded sideways. Yet while SAVA stock has been acting less wild, don’t blame it on a lack of new developments.
Cassava Sciences (NASDAQ:SAVA) stands to gain a good deal this year. This will all depend on the company’s Phase 3 clinical trials progress in the results on actual patients with Alzheimer’s ...
If volatility is not your bag, then definitely stay away from Cassava Sciences (SAVA) stock. This biotech has been one of 2021’s most volatile, not to mention, controversial names. Ultimately ...
Alzheimer’s disease (AD) is a notoriously difficult condition to treat. In fact, there are currently no available drugs that can halt the advancement of the memory-destroying disease. Finding a ...